Profile
Jacob J.
Clement joined MIGENIX, Inc. in August 2002.
He is Chief Science Officer and Senior Vice President-Science and Technology for MIGENIX.
Previously, he held various executive and senior management positions with Abbott Laboratories, Scriptgen Pharmaceuticals and Essential Therapeutics.
Dr. Clement received a PhD and a MSPH from the University of North Carolina, an MS degree from Roosevelt University and a BA degree from St. Mary's University.
Former positions of Jacob J. Clement
| Companies | Position | End |
|---|---|---|
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Chief Tech/Sci/R&D Officer | 2009-01-30 |
Training of Jacob J. Clement
| The University of North Carolina at Charlotte | Doctorate Degree |
| Roosevelt University | Graduate Degree |
| Saint Mary's University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Jacob J. Clement
